Onkologie. 2007:1(2):87-88

Sunitinib je účinný v léčbě pokročilého karcinomu ledvin

Jaroslav Němec
Kuwait Cancer Control Center, Medical Oncology

Published: October 23, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Němec J. Sunitinib je účinný v léčbě pokročilého karcinomu ledvin. Onkologie. 2007;1(2):87-88.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams N, Lee LB, Murray LJ, Ptyer NK, Cherrington JM. SU1 1248 inhibits KIT and plateletderived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
    2. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005; 28: 192-211. [Erratum, Eval Health Prof2005; 28: 370]. Go to original source... Go to PubMed...
    3. Cella D, Yount S, Du H et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 2006; 4: 191-199. Go to original source... Go to PubMed...
    4. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579. Go to original source... Go to PubMed...
    5. Coppin C, Porzsolt F, Awa A, KumpfJ, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1: CDO01425. Go to original source... Go to PubMed...
    6. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1990.
    7. Doing data analysis with the multilevel model for change. In: Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press, 2003: 75-137.
    8. Fisher RI, Rosenberg SA, Fyfe G. Longterm survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: Suppl1: S55-S57.
    9. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Longterm response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin OncoI1996; 14: 2410-2411. Go to original source... Go to PubMed...
    10. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90. Go to original source... Go to PubMed...
    11. Iliopoulos O, Levy AP, Jiang C, Kaelin WG JR, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10595-10599. Go to original source... Go to PubMed...
    12. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852. Go to original source... Go to PubMed...
    13. Kammula US, Whitte DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998; 83: 797-805. Go to original source... Go to PubMed...
    14. Lam JS, Leppert T, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J UroI2005; 23: 202-212. Go to original source... Go to PubMed...
    15. Lan KKG, DeMets DL. Discrete se quential boundaries for clinical trials. Biometrika 1983; 70: 659-663. Go to original source...
    16. Linear mixed effects models. In: Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken, NJ: Wiley-Interscience, 2004: 187-236.
    17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
    18. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275. Go to original source... Go to PubMed...
    19. McDermott DF, Regan MM, Clark I, et al. Randomized phase III trial of highdose interleukin2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141. [Erratum, J Clin OncoI2005; 23: 2877]. Go to original source... Go to PubMed...
    20. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal cell carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17. Go to original source...
    21. Mekhail TM, Abou-Jawde RM, Boumerbi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841. Go to original source... Go to PubMed...
    22. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU1 1248, a novel tyrosine kinase inhibitor targeting vascular endothelial growtb factor and plateletderived growtb factor receptors: determination of a pbarmacokineticlpharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
    23. Motzer RI, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296. Go to original source... Go to PubMed...
    24. Motzer RI, Michaelson MD, Redman BG et al. Activity of SU1 1248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin OncoI2006; 24: 16-24. Go to original source... Go to PubMed...
    25. Motzer RI, Rini BI, Bukowski RM et aJ. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524. Go to original source... Go to PubMed...
    26. Motzer RI, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417. Go to original source... Go to PubMed...
    27. Motzer R, Bander NH, Nanus DM. Renal-cell carcinoma. N Eng! J Med 1996; 335: 865-875. Go to original source... Go to PubMed...
    28. Motzer R, Murphy BA, Bacik J et al. Phase III trial ofinterferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980. Go to original source... Go to PubMed...
    29. Na X, Wu G, Ryan CK, Schoen SR, di' Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxiainducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003; 170: 588-592. Go to original source... Go to PubMed...
    30. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Eng! J Med 1998; 338: 1272-1278. Go to original source... Go to PubMed...
    31. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) ofintermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc Am Soc Clin Oncol 2005; 23: 380s. abstract. Go to original source...
    32. O' Farrell AM, Abrams n, Yuen HA et al. SU1 1248 is a novel FLB tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605. Go to original source... Go to PubMed...
    33. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. Go to original source... Go to PubMed...
    34. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867. Go to original source... Go to PubMed...
    35. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. Go to original source... Go to PubMed...
    36. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth fuctor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434. Go to original source... Go to PubMed...
    37. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3U7-32. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.